Biotech Values

[DonShimoda]

I've never implicitly handicapped the three trials. I merely pointed out that, of the 3 trials, Eyeguard B is the only one with Ph2 results which introduces an additional risk factor to the investment decision. For the record, I agree with your and iwfal's assessment.